03-11-2022 дата публикации
Номер: US20220348879A1
Автор:
Chen Yanxia,
GAO Tingting,
GUO Baojie,
HAO Jie,
Hu Baoyang,
Li Wei,
LI Zhongwen,
Wang Hongmei,
Wang Liu,
Wu Jun,
Zhou Qi
Принадлежит:
The present invention relates to the field of cell therapy, and specifically relates to a method for producing a mesenchymal stem cell population, the mesenchymal stem cell population and a culture supernatant thereof produced by the method, and a pharmaceutical composition containing such cells or the culture supernatant thereof. The present invention further relates to use of the mesenchymal stem cell population and the culture supernatant thereof for preventing and treating diseases. 1. A mesenchymal stem cell population , wherein the mesenchymal stem cell population has an average MMP1 expression level of at least about 10 times higher than that of a primary mesenchymal stem cell; and/or , the mesenchymal stem cell population has an average PGE2 expression level of at least about 10 times higher than that of a primary mesenchymal stem cell.2. The mesenchymal stem cell population according to claim 1 , which has the following characteristics: the mesenchymal stem cell population has an average PD-L1 expression level higher than that of a primary mesenchymal stem cell after being stimulated by IFN-γ;preferably, the mesenchymal stem cell population has an average PD-L1 expression level of at least 2 times higher than that of a primary mesenchymal stem cell after being stimulated by IFN-γ.3. The mesenchymal stem cell population according to or claim 1 , wherein the mesenchymal stem cell population has a cell expressing CD24;preferably, the proportion of CD24+ cells is not less than 50%.4. The mesenchymal stem cell population according to any one of to claim 1 , wherein the mesenchymal stem cell population further has the following characteristics:(1) comprising ≥80% (e.g., ≥85%, ≥90%, ≥95%, ≥96%, ≥97%, ≥98%, ≥99%, or 100%) of cells expressing one or more selected from the group consisting of CD105, CD73, CD90, CD13, CD29, CD44, CD166 and HLA-ABC;(2) comprising ≤2% (e.g., ≤1%, ≤0.5%, ≤0.2%, ≤0.1%, or ≤0.01%) of cells expressing one or more selected from the group ...
Подробнее